Immunology of Graft Rejection

Kidney Transplantation

Volumn , Issue , 2008, Pages 9-32

  Dallman, Margaret J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882515128     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3343-1.50006-2     Document Type: Chapter

References (394)

1. Alard P, Lantz O, Perrot JY, et al. A possible role for specific 'anergy' in immunologic hyporeactivity to donor stimulation in human kidney allograft recipients. Transplantation 1993, 55:277-283.
2. Amsen D, Blander JM, Lee GR, et al. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 2004, 117:515-526.
3. Antonysamy MA, Fanslow WC, Fu F, et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999, 162:577-584.
4. Apasov SG, Sitkovsky MV Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class 1-deficient mice in response to immunization with tumor cells. J Immunol 1994, 152:2087-2097.
5. Armstrong HE, Bolton EM, McMillan I, et al. Prolonged survival of actively enhanced rat renal allografts despite accelerated cellular infiltration and rapid induction of both class I and class II MHC antigens. J Exp Med 1987, 165:891-907.
6. Auchincloss H, Lee R, Shea S, et al. The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 1993, 90:3373-3377.
7. Auchincloss H, Sultan H Antigen processing and presentation in transplantation. Curr Opin Immunol 1996, 8:681-687.
8. Baddoura FK, Nasr IW, Wrobel B, et al. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 2005, 5:510-516.
9. Basadonna G, Matas A, Gillingham K, et al. Relationship between early vs late acute rejection and onset of chronic rejection in kidney transplantation. Transplant Proc 1993, 25:910-911. (1 Pt 2).
10. Bedford P, Garner K, Knight SC MHC class II molecules transferred between allogeneic dendritic cells stimulate primary mixed leukocyte reactions. Int Immunol 1999, 11:1739-1744.
11. Belich MP, Trowsdale J Proteosome and class I antigen processing and presentation. Mol Biol Rep 1995, 21:53-56.
12. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995, 377:630-632.
13. Bevan MJ Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 oncogenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976, 143:1283-1288.
14. Billingham R, Silvers WK Immunobiology of Transplantation 1971, Prentice-Hall, Upper Saddle River, NJ.
15. Billingham RE, Silvers WK Studies on homografts of foetal and infant skin and further observations on the anomalous properties of pouch skin grafts in hamsters. Proc R Soc Lond B Biol Sci 1964, 161:168-190.
16. Bix M, Liao NS, Zijlstra M, et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 1991, 349:329-331.
17. Bjorkman PJ, Saper MA, Samraoni B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987, 329:506-512.
18. Bjorkman PJ MHC restriction in three dimensions: a view of the T cell receptor/ligand interactions. Cell 1997, 89:167-170.
19. Bolling S, Kunkel SL, Lin H Prolongation of cardiac allograft survival in rats by anti-TNF and cyclosporin combination therapy. Transplantation 1992, 53:283-286.
20. Borrego F, Masilamani M, Marusina AI, et al. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res 2006, 35:263-278.
21. Bradley JA, Mason DW, Morris PJ Evidence that rat renal allografts are rejected by cytotoxic T cells and not by non-specific effectors. Transplantation 1985, 39:169-175.
22. Brazelton TR, Morris RE Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996, 8:710-720.
23. Brown KM, Kondeatis E, Vaughan RW, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 2006, 354:2014-2023.
24. Brusic V, Bajic VB, Petrovsky N Computational methods for prediction of T-cell epitopes-a framework for modelling, testing, and applications. Methods 2004, 34:436-443.
25. Bugeon L, Cuturi M-C, Hallet M-M, et al. Peripheral tolerance of an allo-graft in adult rats-characterization by low interleukin-2 and interferonγ mRNA levels and by strong accumulation of major histocompatibility complex transcripts in the graft. Transplantation 1992, 54:219-225.
26. Burdick JF, Clow LW Rejection of primarily vascularized heart grafts, III: depression of the interleukin 2 mechanism early after grafting. Transplantation 1990, 50:476-481.
27. Busch GJ, Galvanek E, Reynolds ES Human renal allografts: analysis of lesions in long-term survivors. Hum Pathol 1971, 2:253.
28. Butcher EC The regulation of lymphocyte traffic. Curr Top Microbiol Immunol 1986, 128:85-122.
29. Butcher EC, Picker LJ Lymphocyte homing and homeostasis. Science 1996, 272:60-66.
30. Calne RY, Sellse RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969, 223:472-476.
31. Campbell RD, Trowsdale J Map of the human major histocompatibility complex. Immunol Today 1993, 14:349-352.
32. Campos L, Naji A, Deli BC, et al. Survival of MHC-deficient mouse heterotopic cardiac allografts. Transplantation 1995, 59:187-191.
33. Cantrell D, Bluestone J, Vivier E, et al. Signalling through the TCR. Res Immunol 1998, 149:866-867.
34. Carlin LM, Yanagi K, Verhoef A, et al. Secretion of IFN-gamma and not IL-2 by anergic human T cells correlates with assembly of an immature immune synapse. Blood 2005, 106:3874-3879.
35. Carroll MC The complement system in regulation of adaptive immunity. Nat Immunol 2004, 5:981-986.
36. Cemerski S, Shaw A Immune synapses in T-cell activation. Curr Opin Immunol 2006, 18:298-304.
37. Chan SY, DeBruyne LA, Goodman RE, et al. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995, 59:1155-1161.
38. Chen J, Myllarniemi M, Akyurek LM, et al. Identification of differentially expressed genes in rat aortic allograft vasculopathy. Am J Pathol 1996, 149:597-611.
39. Clarkson MR, Sayegh MH T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005, 80:555-563.
40. Cobbold SP, Jayasuriya A, Nash A, et al. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 1984, 312:548-551.
41. Cobbold SP, Adams E, Graca L, et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 2006, 213:239-255.
42. Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201-210.
43. Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995, 9:899-909.
44. Colonna M, Brooks EG, Falco M, et al. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993, 260:1121-1124.
45. Colvin RB, Smith RN Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005, 5:807-817.
46. Cose S, Brammer C, Khanna KM, et al. Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway. Eur J Immunol 2006, 36:1423-1433.
47. Cose S T-cell migration: a naive paradigm?. Immunology 2007, 120:1-7.
48. Cosimi AB, Conti D, Delmonico FL, et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990, 144:4604-4612.
49. Cramer DV, Qian S, Harnaha J, et al. Cardiac transplantation in the rat, I: the effect of histocompatibility differences on graft arteriosclerosis. Transplantation 1989, 47:414-419.
50. Cramer DV, Wu GD, Chapman FA, et al. Lymphocyte subsets and histopathologic changes associated with the development of heart transplant arteriosclerosis. J Heart Lung Transplant 1992, 11:458.
51. Cresswell P Assembly, transport and function of MHC class II molecules. Annu Rev Immunol 1994, 12:259-293.
52. Daar AS, Fuggle SV, Hart DNJ, et al. Demonstration and phenotypic characterisation of HLA-DR positive interstitial dendritic cells widely distributed in human connective tissue. Transplant Proc 1983, 15(Suppl 1):311-315.
53. Dai Z, Lakkis FG The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Curr Opin Immunol 1999, 11:504-508.
54. Dallman MJ, Mason DW, Webb M Induction of Ia antigens on murine epidermal cells during the rejection of skin allografts. Eur J Immunol 1982, 12:511-518.
55. Dallman MJ, Mason DW, Webb M The roles of host and donor cells in the rejection of skin allografts by T cell-deprived rats injected with syngeneic T cells. Eur J Immunol 1982, 12:511-518.
56. Dallman MJ, Wood KJ, Morris PJ Specific cytotoxic T cells are found in the non-rejected kidneys of blood transfused rats. J Exp Med 1987, 165:566-571.
57. Dallman MJ, Porter ACG, Larsen CP, et al. Lymphokine production in allografts-analysis of RNA by northern blotting. Transplant Proc 1989, 21:296-298.
58. Dallman MJ, Larsen CP, Morris CP Cytokine gene transcription in vascularised organ grafts-analysis using semiquantitative polymerase chain reaction. J Exp Med 1991, 174:493-496.
59. Dallman MJ, Shiho O, Page TH, et al. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991, 173:79-87.
60. Dallman MJ Cytokines as mediators of organ graft rejection and tolerance. Curr Opin Immunol 1993, 5:788-793.
61. Dallman MJ, Wood KJ, Hamano K, et al. Cytokines and peripheral tolerance to alloantigen. Immunol Rev 1993, 133:5-18.
62. Dallman MJ Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol 1995, 7:632-638.
63. Dallman MJ, Smith E, Benson RA, et al. Notch: control of lymphocyte differentiation in the periphery. Curr Opin Immunol 2005, 17:259-266.
64. Dalloul AH, Chmouzis E, Ngo K, et al. Adoptively transferred CD4+ lymphocytes from CD8-/- mice are sufficient to mediate rejection of MHC class II or class I disparate skin grafts. J Immunol 1996, 156:411-414.
65. Dalloul AH, Ngo K, Fung-Leing W-P CD4-negative cytotoxic T cells with a T cell receptor alpha/beta intermediate expression in CD8-deficient mice. Eur J Immunol 1996, 26:213-218.
66. Davis DM, Chui I, Fassett M, et al. The human natural killer cell synapse. Proc Natl Acad Sci USA 1999, 96:15062-15067.
67. Davis DM, Dustin ML What is the importance of the immunological synapse?. Trends Immunol 2004, 25:323-327.
68. de Waal RMW, Bogman MJJ, Mass CN, et al. Variable expression of Ia antigens on the vascular endothelium of mouse skin allografts. Nature (Lond) 1983, 303:426-429.
69. Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991, 88:346-350.
70. Delikouras A, Dorling A Transplant accommodation. Am J Transplant 2003, 3:917-918.
71. Delikouras A, Fairbanks LD, Simmonds AH, et al. Endothelial cell cytoprotection induced in vitro by allo- or xenoreactive antibodies is mediated by signaling through adenosine A2 receptors. Eur J Immunol 2003, 33:3127-3135.
72. Demetris AJ, Zerbe T, Banner B Morphology of solid organ allograft arteriopathy: identification of proliferating intimal cell populations. Transplant Proc 1989, 21:3667-3669.
73. DeVries ME, Ran L, Kelvin D On the edge: the physiological and pathophysiological role of chemokines during inflammatory and immunological responses. Semin Immunol 1999, 11:95-104.
74. Dierich A, Chan SH, Benoist C, et al. Graft rejection by T cells not restricted by conventional major histocompatibility complex molecules. Eur J Immunol 1993, 23:2725-2728.
75. Dorling A, Lechler RI The passenger leucocyte, dendritic cell and antigen-presenting cell (APC). Transplantation Biology: Cellular and Molecular Aspects 1996, 355. Lippincott-Raven, Philadelphia. N.L. Tilney, T.B. Strom, L.C. Paul (Eds.).
76. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation-special reference to the significance of a positive crossmatch. Ann Surg 1996, 224:168-177.
77. Duijvestijn AM, Van Breda Vriesman PJC Chronic renal allograft rejection: selective involvement of the glomerular endothelium in humoral immune reactivity and intravascular coagulation. Transplantation 1991, 52:195-202.
78. Dvorak HF, Mihm MCJ, Dvorak AM, et al. Rejection of first-set skin allografts in man-the micro vasculature is the critical target of the immune response. J Exp Med 1979, 150:322-337.
79. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, et al. Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 2006, 18:92-97.
80. Engers HD, Glasebrooke AL, Sorenson GD Allogeneic tumour rejection induced by the intravenous injection of Lyt-2+ cytolytic T lymphocyte clones. J Exp Med 1982, 156:1280-1285.
81. Fabre JW, Morris PJ Studies on the specific suppression of renal allograft rejection in presensitised rats. Transplantation 1975, 19:121-133.
82. Fairchild RL, VanBuskirk AM, Kondo T, et al. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation 1997, 63:1807-1812.
83. Fangmann J, Dalchau R, Fabre JW Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 1992, 175:1521-1529.
84. Farges O, Morris PJ, Dallman MJ Spontaneous acceptance of liver allografts in the rat: analysis of the immune response. Transplantation 1994, 57:171-177.
85. Farges O, Morris PJ, Dallman MJ Spontaneous acceptance of rat liver allografts is associated with an early down regulation of intragraft IL-4 mRNA expression. Hepatology 1995, 21:767-775.
86. Fellous M, Nir U, Wallach D, et al. Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. Proc Natl Acad Sci USA 1982, 79:3082-3086.
87. Florey HW, Jennings MA General Pathology 1970, 124-174. Lloyd-Luke, London. 4th ed. H.W. Florey (Ed.).
88. Foster P, Sankary HN, Hart M Blood and graft eosinophilia as predictors of rejection in human liver transplantation. Transplantation 1989, 47:72-74.
89. Frasca L, Carmichael P, Lechler R, et al. Anergic T cells effect linked suppression. Eur J Immunol 1997, 27:3191-3197.
90. Freeman GJ, Boussiotis VA, Anumanthan A, et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995, 2:523-532.
91. Fuggle S, McWhinnie DL, Chapman JR, et al. Sequential analysis of HLA-class II antigen expression in human renal allografts. Transplantation 1986, 42:144-150.
92. Gaiano N, Fishell G The role of Notch in promoting glial and neural stem cell fates. Annu Rev Neurosci 2002, 25:471-490.
93. Gainer AL, Suarez-Pinzon WL, Min WP, et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998, 66:194-199.
94. Gajewski TF, Fitch FW Anti-proliferative effect of IFNγ in immune regulation, I: IFNγ inhibits the proliferation of TH2 but not TH1 murine helper T lymphocyte clones. J Immunol 1988, 140:4245-4252.
95. Gajewski TF, Schell SR, Nau G, et al. Regulation of T cell activation: differences among T-cell subsets. Immunol Rev 1989, 111:79-110.
96. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000, 105:35-44.
97. Garcia KC, Degano M, Stanfield RL, et al. An αβ T cell receptor structure at 2.5A and its orientation in the TCR-MHC complex. Science 1996, 274:209-219.
98. Germain RN, Margulies DH The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993, 11:403-450.
99. Gibson JM, Medawar PB The fate of skin homografts in man. J Anat 1943, 77:299-310.
100. Glotz D, Lucchiari N, Pegaz-Fiornet B, et al. Endothelial cells as targets of allograft rejection. Transplantation 2006, 82(1 Suppl):S19-S21.
101. Golding H, Singer A Role of accessory cell processing and presentation of shed H-2 alloantigens in allospecific cytotoxic T lymphocyte responses. J Immunol 1984, 133:597-605.
102. Goldman M, Le Moine A, Braun M, et al. A role for eosinophils in transplant rejection. Trends Immunol 2001, 22:247-251.
103. Goldstein DR, Tesar BM, Akira S, et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003, 111:1571-1578.
104. Gorczynski RM Immunosuppression induced by hepatic portal venous immunization spares reactivity in IL-4 producing T lymphocytes. Immunol Lett 1992, 33:67-78.
105. Gorer PA The antigenic basis of tumour transplantation. J Pathol Bacteriol 1938, 47:231-252.
106. Goulmy E Class I restricted human cytotoxic T lymphocytes directed against minor transplantation antigens and their role in organ transplantation. Prog Allergy 1985, 36:44-72.
107. Goulmy E Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 2006, 67:433-438.
108. Gowans JL The recirculation of lymphocytes from blood to lymph in the rat. J Physiol 1959, 146:54-68.
109. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999, 285:221-227.
110. Grandaliano G, Gesualdo L, Ranieri E, et al. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 1997, 63:414-420.
111. Greenfield A, Scott D, Pennisi D, et al. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat Genet 1996, 14:474-478.
112. Greenwald RJ, Freeman GJ, Sharpe AH The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
113. Grey HM, Chestnut R Antigen processing and presentation to T cells. Immunol Today 1985, 6:101-106.
114. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192.
115. Gummert JF, Ikonen T, Morris RE Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999, 10:1366-1380.
116. Gurley KE, Lowry RP, Clarke-Forbes RD Immune mechanisms in organ allograft rejection, II: T helper cells, delayed type hypersensitivity and rejection of renal allografts. Transplantation 1983, 36:401-405.
117. Hall BM, DeSaxe I, Dorsch SE The cellular basis of allograft rejection in vivo: restoration of first set rejection of heart grafts by T helper cells in irradiated rats. Transplantation 1983, 36:700-705.
118. Hamawy MM Targeting proximal T cell receptor signaling in transplantation. Transplantation 2003, 75:1921-1927.
119. Hamel ME, Noteboom E, Kruisbeek AM Non-responsiveness of antigen-experienced CD4 T cells reflects more stringent costimulatory requirements. Immunology 1998, 93:366-375.
120. Hancock WH, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules and the pathogenesis of chronic rejection in rat renal allografts. Transplantation 1993, 56:643-650.
121. Hancock WW, Gao W, Csizmadia V, et al. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001, 193:975-980.
122. Hancock WW Chemokines and transplant immunobiology. J Am Soc Nephrol 2002, 13:821-824.
123. Hancock WW, Wang L, Ye Q, et al. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003, 15:479-486.
124. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
125. Harrington LE, Mangan PR, Weaver CT Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006, 18:349-356.
126. Harshyne LA, Watkins SC, Gambotto A, et al. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001, 166:3717-3723.
127. Hart DN, Fabre JW Kidney-specific alloantigen system in the rat: characterisation and role in transplantation. J Exp Med 1980, 151:651-666.
128. Hart DN, Fabre JW Demonstration and characterisation of Ia positive dendritic cells in the interstitial connective tissues of the rat heart and other tissues, but not brain. J Exp Med 1981, 154:347-361.
129. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immuno-suppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993, 55:766-773.
130. Hauptmann G, Bahram S Genetics of the central MHC. Curr Opin Immunol 2004, 16:668-672.
131. Hayry P, Defendi V Mixed lymphocyte cultures produce effector cells: model in vitro for allograft rejection. Science 1970, 168:133-135.
132. Hayry P, Mennander A, Raisanen-Sokolowski A, et al. Pathophysiology of vascular wall changes in chronic allograft rejection. Transplant Rev 1993, 7:1-20.
133. Heagy W, Waltenbaugh C, Martz E Potent ability of anti-LFA-1 monoclonal antibody to prolong allograft survival. Transplantation 1984, 37:520-523.
134. Henning G, Ohl L, Junt T, et al. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med 2001, 194:1875-1881.
135. Henretta J, Araneda D, Pittman K, et al. Marked prolongation of incompatible class I deficient heart allografts: paradoxical effects between primarily and secondarily vascularized allografts. Transplant Proc 1995, 27:1303-1304.
136. Herberman RB, Djeu JY, Kay HD, et al. Natural killer cells: characteristics and regulation of activity. Immunol Rev 1979, 44:43-70.
137. Herrera OB, Golshayan D, Tibbott R, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004, 173:4828-4837.
138. Hodes RJ, Svedmyr EAJ Specific cytotoxicity of H-2-incompatible mouse lymphocytes following mixed culture in vitro. Transplantation 1970, 9:470-477.
139. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 1996, 62:1565-1570.
140. Hsieh C-S, Heimberger AB, Gold JS, et al. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an αβ T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992, 89:6065-6069.
141. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 260:547-548.
142. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection, I: evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 1990, 50:219-225.
143. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection, II: evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac survival in rats. Transplantation 1990, 50:189-193.
144. Imagawa DK, Millis JM, Seu P, et al. The role of tumor necrosis factor in allograft rejection, III: evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation 1991, 51:57-62.
145. Ingham-Clark CL, Cunningham AJ, Crane PW, et al. Lymphocyte infiltration patterns in rat small-bowel transplants. Transplant Proc 1990, 22:2460.
146. Iwata T, Kamei Y, Esaki S, et al. Immunosuppression by anti-ICAM-1 and anti-LFA-1 monoclonal antibodies of free and vascularized skin allograft rejection. Immunobiology 1996, 195:160-171.
147. Janeway CA, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease 2005, Garland Science Publishing, New York. 6th ed.
148. Jenkins MK, Pardoll DM, Mizuguchi J, et al. Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T lymphocyte clones. Proc Natl Acad Sci USA 1987, 84:5409-5413.
149. Jenkins MK, Schwartz RH Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987, 165:302-319.
150. Josien R, Pannetier C, Douillard P, et al. Graft infiltrating T helper cells CD45RC phenotype and TH1/TH2-related cytokines in donor specific transfusion-induced tolerance in adult rats. Transplantation 1995, 60:1131-1139.
151. Kagi D, Seiler P, Pavlovic J, et al. The roles of perforin- and Fasdependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995, 25:3256-3262.
152. Kamada N, Davies H, Roser B Reversal of transplantation of immunity by liver grafting. Nature 1981, 292:840-842.
153. Kamada N, Wight DGD Antigen-specific immunosuppression induced by liver transplantation in the rat. Transplantation 1984, 38:217-222.
154. Kamada N Experimental liver transplantation 1988, CRC Press, Boca Raton, Fla.
155. Karre K NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002, 55:221-228.
156. Katsura Y Cell-mediated and humoral immune responses in mice, III: dynamic balance between delayed-type hypersensitivity and antibody response. Immunology 1977, 32:227-235.
157. Kauntz SL, Williams MA, Williams PL, et al. Mechanism of rejection of homotransplanted kidneys. Nature 1963, 199:257-260.
158. Kawai K, Shahinian A, Mak TW, et al. Skin allograft rejection in CD28-deficient mice. Transplantation 1996, 61:252-255.
159. Kim PC, Levy GA, Koh I, et al. Immunologic basis of small intestinal allograft rejection. Transplant Proc 1991, 23:830.
160. Kindt TJ, Goldsby RA, Osborne BA Kuby: Immunology 2004, WH Freeman, New York. 4th ed.
161. King KE, Warren DS, Samaniego-Picota M, et al. Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol 2004, 16:545-549.
162. Kirby JA Function of leucocyte adhesion molecules during allograft rejection. Transplantation Biology: Cellular and Molecular Aspects 1996, Lippincott-Raven, Philadelphia. N.L. Tilney, T.B. Strom, L.C. Paul (Eds.).
163. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999, 5:686-693.
164. Kirkman RL, Colvin RB, Flye MW, et al. Transplantation in miniature swine. Transplantation 1979, 28:24-30.
165. Kirwan SE, Burshtyn DN Regulation of natural killer cell activity. Curr Opin Immunol 2007, 19:46-54.
166. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet 1966, 2:662-665.
167. Kitchens WH, Uehara S, Chase CM, et al. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006, 81:811-817.
168. Klein J, Chiang CL, Hauptfeld V Histocompatibility antigens controlled by the I region of the murine H-2 complex. J Exp Med 1977, 145:450-454.
169. Klein J, Juretic A, Baxevanis CN, et al. The traditional and a new version of the mouse H-2 complex. Nature 1981, 291:455-460.
170. Koga S, Novick AC, Toma H, et al. CD8+ T cells produce RANTES during acute rejection of murine allogeneic skin grafts. Transplantation 1999, 67:854-864.
171. Konieczny BT, Saleem S, Lowry RP, et al: Vigorous cardiac allograft rejection in IFN gamma knockout mice. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicians 170, 1996.
172. Koo DD, Welsh KI, Roake JR, et al. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998, 153:557-566.
173. Kormendi F, Amend WJC The importance of eosinophil cells in kidney allograft rejection. Transplantation 1988, 45:537-539.
174. Krieger NR, Yin D-P, Fathman CG CD4+ but not CD8+ cells are essential for allorejection. J Exp Med 1996, 184:2013-2018.
175. Kuchroo VK, Das MP, Brown JA, et al. B7.1 and B7.2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease. Cell 1995, 80:707-718.
176. Kudig T, Shahinian A, Kawai K, et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 1996, 5:41-52.
177. Laden AMK, Sinclair RA Thickening of arterial intima in rat cardiac allografts. Am J Pathol 1971, 63:69-84.
178. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997, 158:2443-2448.
179. Lakkis FG, Arakelov A, Konieczny BT, et al. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000, 6:686-688.
180. Lakkis FG Where is the alloimmune response initiated?. Am J Transplant 2003, 3:241-242.
181. Lamouse-Smith E, Clements VK, Ostrand-Rosenberg S Beta 2M-/-knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol 1993, 151:6283-6290.
182. Lampert IA, Suitters AJ, Chisholm PM Expression of Ia antigen on epidermal keratinocytes in graft-versus-host disease. Nature 1981, 293:149-150.
183. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
184. Larsen CP, Morris PJ, Austyn JM Migration of dendritic leucocytes from cardiac allografts into host spleens: a novel pathway for initiation of rejection. J Exp Med 1990, 171:307-314.
185. Larsen CP, Steinman RM, Witmer-Pack M, et al. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990, 172:1483-1493.
186. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996, 61:4-9.
187. Larsen CP, Elwood ET, Alexander DZ, et al. Long term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
188. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006, 6:876-883. (5 Pt 1).
189. Laskowski I, Pratschke J, Wilhelm MJ, et al. Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transplant 2000, 5:29-35.
190. Lau HT, Yu M, Fontana A, et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996, 273:109-112.
191. Le Bas-Bernardet S, Hourmant M, Valentin N, et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003, 75:477-482.
192. Le Moine A, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5 and eosinophils in chronic skin allograft rejection. J Clin Invest 1999, 103:1659-1667.
193. Le Moine A, Surquin M, Demoor FX, et al. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. J Immunol 1999, 163:3778.
194. Lee RS, Grusby MJ, Glimcher LH, et al. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med 1994, 179:865-872.
195. Lee RS, Grusby MJ, Laufer TM, et al. CD8+ effector cells responding to residual class I antigens, with help from CD4+ cells stimulated indirectly cause rejection of "major histocompatibility complex-deficient" skin grafts. Transplantation 1997, 63:1123-1133.
196. Lehner PJ, Cresswell P Recent developments in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004, 16:82-89.
197. Leibson PJ MHC-recognising receptors: they're not just for T cells anymore. Immunity 1995, 3:5-8.
198. Lenschow DJ, Herold KC, Rhee L, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996, 5:285-293.
199. Lentsch AB, Yoshidome H, Cheadle WG, et al. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC [corrected and republished article originally printed in Hepatology 27(2): 507-512, 1998]. Hepatology 1998, 27:1172-1177.
200. Li X, Faustman D Use of donor beta 2-microglobulin-deficient transgenic mouse liver cells for isografts, allografts and xenografts. Transplantation 1993, 55:940-946.
201. Little CC, Tyzer EE Further experimental studies on the inheritance of susceptibility to a transplantable tumour carcinoma (JWA) of the Japanese Waltzing mouse. J Med Res 1916, 33:393-453.
202. Ljunggren HG, Karre K In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-244.
203. Lombardi G, Sidhu S, Batchelor R, et al. Anergic T cells as suppressor cells in vitro. Science 1994, 264:1587-1589.
204. Long EO, Wagtmann N Natural killer cell receptors. Curr Opin Immunol 1997, 9:344-350.
205. Loveland BE, Hogarth PM, Ceredig R, et al. Delayed type hypersensitivity and allograft rejection in the mouse: correlation of effector cell phenotype. J Exp Med 1981, 153:1044-1057.
206. Loveland BE, McKenzie IFC Cells mediating graft rejection in the mouse. Immunology 1982, 46:313-320.
207. Lowry RP, Gurley KE, Clarke-Forbes RD Immune mechanisms in organ allograft rejection, 1: delayed type hypersensitivity and lymphocytotoxicity in heart graft rejection. Transplantation 1983, 36:391-401.
208. Lowry RP, Blais D Tumour necrosis factor alpha in rejecting rat cardiac allografts. Transplant Proc 1988, 20:245-247.
209. Lunsford KE, Horne PH, Koester MA, et al. Activation and maturation of alloreactive CD4-independent, CD8 cytolytic T cells. Am J Transplant 2006, 6:2268-2281.
210. Macatonia SE, Doherty TM, Knight SC, et al. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFNγ production. J Immunol 1993, 150:3755-3765.
211. Macatonia SE, Hsieh C-S, O'Garra A, et al. Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gamma-dependent. Int Immunol 1993, 5:1119-1128.
212. Mackay CR Homing of naive, memory and effector lymphocytes. Curr Opin Immunol 1993, 5:423-427.
213. Mackay CR Immunological memory. Adv Immunol 1993, 53:217-265.
214. Madsen JC, Peugh WN, Wood KJ, et al. The effect of anti-L3T4 monoclonal antibody treatment on first set rejection of murine cardiac allografts. Transplantation 1987, 44:849-852.
215. Madsen JC, Superina RA, Wood KJ, et al. Induction of immunological unresponsiveness using recipient cells transfected with donor MHC genes. Nature (Lond) 1988, 332:161-164.
216. Mahnke K, Enk AH Dendritic cells: key cells for the induction of regulatory T cells?. Curr Top Microbiol Immunol 2005, 293:133-150.
217. Mandal AK, Snyder JJ, Gilbertson DT, et al. Does cadaveric donor renal transplantation ever provide better outcomes than live-donor renal transplantation?. Transplantation 2003, 75:494-500.
218. Mandelbrot DA, Furukawa Y, McAdam AJ, et al. Expression of B7 molecules in recipient, not donor mice determines the survival of cardiac allografts. J Immunol 1999, 163:3753-3757.
219. Mandrup-Poulsen T, Bendtzen K, Nerup J, et al. Affinitypurified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986, 29:63-67.
220. Mandrup-Poulsen T, Helqvist S, Molvig J, et al. Cytokines as immune effector molecules in autoimmune endocrine diseases with special reference to insulindependent diabetes mellitus. Autoimmunity 1989, 4:191-218.
221. Mannon RB, Nataraj C, Kotzin BL, et al. Rejection of kidney allografts by MHC class 1-deficient mice. Transplantation 1995, 59:746-755.
222. Marelli-Berg FM, Barroso-Herrera O, Lechler RI Recently activated T cells are costimulation-dependent in vitro. Cell Immunol 1999, 195:18-27.
223. Marelli-Berg FM, Frasca L, Weng L, et al. Antigen recognition influences transendothelial migration of CD4+ T cells. J Immunol 1999, 162:696-703.
224. Markmann JF, Bassiri H, Desai NM, et al. Indefinite survival of MHC class I-deficient murine pancreatic islet allografts. Transplantation 1992, 54:1085-1089.
225. Mason DW, Dallman MJ, Barclay AN Graft-versus-host disease induces expression of Ia antigen in rat epidermal cells and gut epithelium. Nature 1981, 293:150-151.
226. Mason DW, Morris PJ Inhibition of the accumulation, in rat kidney allografts, of specific-but not nonspecific-cytotoxic cells by cyclosporine. Transplantation 1984, 37:46-51.
227. Matzinger P Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
228. McCurry KR, Colvin BL, Zahorchak AF, et al. Regulatory dendritic cell therapy in organ transplantation. Transpl Int 2006, 19:525-538.
229. McEver RP, Beckstead JH, Moore KL, et al. GMP-140, a platelet alphagranule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989, 84:92-99.
230. McKnight AJ, Barclay AN, Mason DW Molecular cloning of rat inter-leukin 4 cDNA and anlaysis of the cytokine repertoire of subsets of CD4+ T cells. Eur J Immunol 1991, 21:1187-1194.
231. McLean AG, Hughes D, Welsh KI, et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantion. Transplantation 1997, 63:374-380.
232. Medawar PB Behaviour and fate of skin autografts and skin homografts in rabbits. J Anat 1944, 78:176-199.
233. Medawar PB A second study of the behaviour and fate of skin homografts in rabbits. J Anat 1945, 79:157-176.
234. Medzhitov R, Janeway CAJ Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91:295-298.
235. Mellor AL, Munn DH Immune privilege: a recurrent theme in immunoregulation. Immunol Rev 2006, 213:5-11.
236. Mellor AL, Munn DH Immune privilege. Immunol Rev 2006, 213:5-257.
237. Mennander A, Tisala S, Paavonen T, et al. Chronic rejection of rat aortic allograft, II: administration of cyclosporine induces accelerated allograft arteriosclerosis. Transpl Int 1991, 4:173-179.
238. Merani S, Truong WW, Hancock W, et al. Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction. Cell Transplant 2006, 15:295-309.
239. Milner CM, Campbell RD Genetic organization of the human MHC class III region. Front Biosci 2001, 6:D914-D926.
240. Mintz B, Silvers WK "Intrinsic" immunological tolerance in allophenic mice. Science 1967, 158:1484-1486.
241. Mintz B, Silvers WK Histocompatibility antigens on melanoblasts and hair follicle cells. Transplantation 1970, 9:497-505.
242. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003, 19:561-569.
243. Mohler KM, Streilein JW Lymphokine production by MLR-reactive reaction lymphocytes obtained from normal mice and mice rendered tolerant of class II MHC antigens. Transplantation 1989, 47:625-633.
244. Monaco JJ Major histocompatibility complex-linked transport proteins and antigen processing. Immunol Res 1992, 11:125-132.
245. Monaco JJ Structure and function of genes in the MHC class II region. Curr Opin Immunol 1993, 5:17-20.
246. Monaco JJ Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 1995, 57:543-547.
247. Monks CR, Freiberg BA, Kupfer H, et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998, 395:82-86.
248. Morikawa M, Tamatani T, Miyasaka M, et al. Cardiac allografts in rat recipients with simultaneous use of anti-ICAM-1 and anti-LFA-1 monoclonal antibodies leads to accelerated graft loss. Immunopharmacology 1994, 28:171-182.
249. Morris PJ, Ting A Studies of HLA-DR with relevance to renal transplantation. Immunol Rev 1982, 66:103-131.
250. Morris RE Rapamycin: FK506's fraternal twin or distant cousin?. Immunol Today 1991, 12:137-142.
251. Morris RE New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993, 12:S275-S286.
252. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone, 1: definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
253. Mosmann TR, Coffman RL TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
254. Mosmann TR, Moore KW The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991, 12:A49-A53.
255. Mueller R, Davies JD, Krahl T, et al. IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J Immunol 1997, 159:1599-1603.
256. Murphy WJ, Kumar V, Bennett M Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID): evidence that NK cells can mediate the specificity of marrow graft rejection. J Exp Med 1987, 165:1212-1217.
257. Murphy WJ, Kumar V, Bennett M Acute rejection of murine bone marrow allografts by matural killer cells and T cells: differences in kinetics and target antigens recognized. J Exp Med 1987, 166:1499-1509.
258. Mustelin T, Tasken K Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J 2003, 371:15-27. (Pt 1).
259. Nemoto T, Burne MJ, Daniels F, et al. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int 2001, 60:2205-2214.
260. Nickerson P, Steurer W, Steiger J, et al. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994, 6:757-764.
261. Nickerson P, Zheng X-X, Steiger J, et al. Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transplant Immunol 1996, 4:81-85.
262. Niederkorn JY The immune privilege of corneal allografts. Transplantation 1999, 67:1503-1508.
263. Nolan CR, Saenz KP, Thomas CA, et al. Role of eosinophils in chronic vascular rejection in renal allografts. Am J Kidney Dis 1995, 26:634-642.
264. O'Brien SJ, Roelke ME, Marker L, et al. Genetic basis for species vulnerability in the cheetah. Science 1985, 227:1428-1434.
265. Obhrai J, Goldstein DR The role of toll-like receptors in solid organ transplantation. Transplantation 2006, 81:497-502.
266. Ohki S, Iizuka K, Ishikawa S, et al. A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model. J Heart Lung Transplant 2001, 20:956-963.
267. Oppenheim JJ, Wang JM, Chertov O, et al. The role of chemokines in transplantation. Transplantation Biology: Cellular and Molecular Aspects 1996, 187-200. Lippincott-Raven, Philadelphia. N.L. Tilney, T.B. Strom, L.C. Paul (Eds.).
268. Orosz CG, Pelletier RP Chronic remodeling pathology in grafts. Curr Opin Immunol 1997, 9:676-680.
269. Osorio RW, Ascher NL, Jaenisch R, et al. Major histocompatibility complex class 1 deficiency prolongs islet allograft survival. Diabetes 1993, 42:1520-1527.
270. Parham P, Clayberger C, Zorn SL, et al. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the OL2 domain of HLA-A2. Nature 1987, 325:625-628.
271. Parham P Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol 2005, 42:459-462.
272. Parish C The relationship between humoral and cell-mediated immunity. Transplant Rev 1972, 13:35-66.
273. Patel R, Terasaki PI Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969, 280:735-739.
274. Paul LC, Benediktsson H Chronic transplant rejection: magnitude of the problem and pathogenetic mechanisms. Transplant Rev 1993, 7:96-113.
275. Paul LC, Hayry P, Foegh M-L, et al. Diagnostic criteria of chronic rejection/accelerated graft atherosclerosis of heart and kidney transplants. Proposal from the fourth Alexis Carrel conference on chronic rejection and accelerated arteriosclerosis in transplanted organs. Transplant Proc 1993, 25:2022-2023.
276. Paul LC, Saito K, Davidoff A, et al. Growth factor transcripts in rat renal transplants. Am J Kidney Dis 1996, 28:441-450.
277. Pearson TC, Alexander DZ, Winn KJ, et al. Transplantation tolerance induced by CTLA-4 Ig. Transplantation 1994, 57:1701-1706.
278. Peng Q, Li K, Patel H, et al. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006, 176:3330-3341.
279. Perlmann P, Holm G Cytotoxic effects of lymphoid cells in vitro. Adv Immunol 1969, 11:117-193.
280. Perlmann P, Perlmann H Contactual lysis of antibody coated chicken erythrocytes by purified lymphocytes. Cell Immunol 1970, 1:300-315.
281. Peugh WN, Superina RA, Wood KJ, et al. The role of H-2 and non-H-2 antigens and genes in the rejection of murine cardiac allografts. Immunogenetics 1986, 23:30-37.
282. Picker LJ, Butcher EC Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 1992, 10:561-591.
283. Picotti JR, Chan SY, VanBuskirk AM, et al. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival?. Transplantation 1997, 63:619-624.
284. Pober JS, Gimbrone MA, Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumour necrosis factor and immune interferon. J Immunol 1986, 137:1893-1896.
285. Porter KA, Calne RY, Zukoski CF Vascular and other changes in 200 renal homotransplants treated with immunosuppressive drugs. Lab Invest 1964, 13:810-824.
286. Powelson JA, Cosimi AB Liver transplantation. Transplantation 1999, 324-373. Blackwell Science, Boston. P.J. Morris, A.B. Cosimi, L.C. Ginns (Eds.).
287. Pratt JR, Basheer SA, Sacks SH Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002, 8:582-587.
288. Qureshi F, Rabb H, Kasiske BL Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival. Transplantation 2002, 74:1400-1404.
289. Rabinovitch A, Pukel C, Baquerizo H Interleukin-1 inhibits glucosemodulated insulin and glucagon secretion in rat islet monolayer cultures. Endocrinology 1988, 122:2393-2398.
290. Rammensee H-G, Falk K, Rotzschke O Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993, 11:213-244.
291. Ranger AM, Das MP, Kuchroo VK, et al. B7-2 (CD86) is essential for the development of IL-4 producing cells. Int Immunol 1996, 8:1549-1560.
292. Reinhardt RL, Kang SJ, Liang HE, et al. T helper cell effector fates-who, how and where?. Curr Opin Immunol 2006, 18:271-277.
293. Reis e Sousa C, Stahl PD, Austyn JM Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993, 178:509-519.
294. Riley JL, June CH The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005, 105:13-21.
295. Rissoan M-C, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283:1183-1186.
296. Robertson H, Wong WK, Talbot D, et al. Tubulitis after renal transplantation: demonstration of an association between CD103+ T cells, transforming growth factor beta1 expression and rejection grade. Transplantation 2001, 71:306-313.
297. Robinson JH, Delvig AA Diversity in MHC class II antigen presentation. Immunology 2002, 105:252-262.
298. Roche PA HLA-DM: an in vivo facilitator of MHC class II peptide loading. Immunity 1995, 3:259-262.
299. Roopenian D, Choi EY, Brown A The immunogenomics of minor histocompatibility antigens. Immunol Rev 2002, 190:86-94.
300. Rose AG, Uys CJ Pathology of graft atherosclerosis (chronic rejection). Transplantation and Replacement of Thoracic Organs 1990, Kluwer Academic, Boston. D.K.C. Cooper, D. Novitsky (Eds.).
301. Rosenberg AS, Mizuochi T, Singer A Analysis of T cell subsets in rejection of Kb mutant skin allografts differing at class I MHC. Nature 1986, 322:829-831.
302. Rosenberg AS, Mizuochi T, Sharrow SO, et al. Phenotype, specificity and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med 1987, 165:1296-1315.
303. Rosenberg AS, Singer A Cellular basis of skin allograft rejection: an in vivo model of immunemediated tissue destruction. Annu Rev Immunol 1992, 10:333-358.
304. Rosenberg AS The T cell populations mediating rejection of MHC class I disparate skin grafts in mice. Transplant Immunol 1993, 2:93-99.
305. Rosenberg SA, Anderson WF, Blaese M, et al. The development of gene therapy for the treatment of cancer. Ann Surg 1993, 218:455-464.
306. Ross R, Glomset JA The pathogenesis of atherosclerosis. N Engl J Med 1976, 295:369-377.
307. Rossen RD, Butler WT, Reisberg MA, et al. Immunofluorescent localisation of human immunoglobulin on tissues from cardiac allograft recipients. J Immunol 1971, 106:171-180.
308. Rossi D, Zlotnik A The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
309. Rotzschke O, Falk K, Faath S, et al. On the nature of peptides involved in T cell alloreactivity. J Exp Med 1991, 174:1059-1071.
310. Rubin RH, Tolkoff Rubin NE The problem of cytomegalovirus in transplantation. Prog Transplant 1984, 1:89.
311. Rudolph MG, Stanfield RL, Wilson IA How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006, 24:419-466.
312. Russell PS, Chase CM, Colvin RB Alloantibody-and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997, 64:1531-1536.
313. Russo V, Zhou D, Sartirana C, et al. Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. Blood 2000, 95:3473-3477.
314. Sakaguchi S Regulatory T cells: key controllers of immunologic selftolerance. Cell 2000, 101:455-458.
315. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
316. Salahudeen AK, Haider N, May W Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 2004, 65:713-718.
317. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001, 1:260-269.
318. Salama AD, Pusey CD Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006, 2:221-230.
319. Saleem S, Konieczny BT, Lowry RP, et al. Acute rejection of vascularized heart allografts in the absence of IFNγ. Transplantation 1996, 62:1908-1911.
320. Santamaria-Babi LF, Moser R, Perez-Soler MT, et al. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4) and the lymphocyte function-associated antigen-1 (LFA-1). J Immunol 1995, 154:1543-1550.
321. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995, 181:1869-1874.
322. Schilham MW, Fung-Leung WP, Rahemtulla A, et al. Alloreactive cytotoxic T cells can develop and function in mice lacking both CD4 and CD8. Eur J Immunol 1993, 23:1299-1304.
323. Schulz M, Schuurman H-J, Joergensen J, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol 1995, 25:474-480.
324. Schwartz JC, Zhang X, Nathenson SG, et al. Structural mechanisms of costimulation. Nat Immunol 2002, 3:427-434.
325. Schwartz RH A cell culture model for T lymphocyte clonal anergy. Science 1990, 248:1349-1356.
326. Schwartz RH T cell clonal anergy. Curr Opin Immunol 1997, 9:351-357.
327. Scott DM, Ehrmann IE, Ellis PS, et al. Identification of a mouse malespecific transplantation antigen, H-Y. Nature 1995, 376:695-698.
328. Scott DM, Ehrmann IE, Ellis PS, et al. Why do some females reject males? The molecular basis for male-specific graft rejection. J Mol Med 1997, 75:103-114.
329. Selvaggi G, Ricordi C, Podack ER, et al. The role of the perforin and Fas pathways of cytotoxicity in skin graft rejection. Transplantation 1996, 62:1912-1915.
330. Sharpe AH, Abbas AK T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006, 355:973-975.
331. Shastri N, Cardinaud S, Schwab SR, et al. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 2005, 207:31-41.
332. Shirwan H Chronic allograft rejection: do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role?. Transplantation 1999, 68:715-726.
333. Shortman K, Liu YJ Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2:151-161.
334. Shreeder V, Moodycliffe AM, Ullrich SE, et al. Dendritic cells require T cells for functional maturation in vivo. Immunity 1999, 11:625-636.
335. Simpson E, Roopenian D, Goulmy E Much ado about minor histocompatibility antigens. Immunol Today 1998, 19:108-112.
336. Snanoudj R, de Preneuf H, Creput C, et al. Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 2006, 19:693-704.
337. Snider ME, Steinmuller D Non-specific tissue destruction as a consequence of cytotoxic T lymphocyte interaction with antigen-specific target cells. Transplant Proc 1987, 19:421-423.
338. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004, 4:1315-1322.
339. Sprent J, Schaeffer M, Lo D, et al. Properties of purified T cell subsets, II: in vivo class I vs class II H-2 differences. J Exp Med 1986, 163:998-1011.
340. Steiger J, Nickerson PW, Steurer W, et al. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995, 155:489-498.
341. Steinman RM, Witmer MD Lymphoid dendritic cells are potent stimulations of the primary mixed leucocyte reaction in mice. Proc Natl Acad Sci USA 1978, 75:5132-5136.
342. Steinman RM, Gutchinov B, Witmer MD, et al. Dendritic cells are the peripheral stimulators of the primary mixed leukocyte reaction in mice. J Exp Med 1983, 157:613-627.
343. Steinman RM The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
344. Steinman RM, Hemmi H Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006, 311:17-58.
345. Steinmuller D, Wachtal SS Passenger leukocytes and induction of allograft immunity. Transplant Proc 1980, 12:100-106.
346. Stepkowski SM, Chen W, Geary R, et al. An oral formulation for intracellular adhesion molecules-1 antisense oligonucleotides. Transplant Proc 2001, 33(7-8):3271.
347. Stepkowski SM Therapeutic potential for adhesion antagonists in organ transplantation. Curr Opin Organ Transplant 2002, 7:366-372.
348. Strom TB, Roy-Chadhury P, Manfro R, et al. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol 1996, 8:688-693.
349. Subramanian S, Bowyer MW, Egan JC, et al. Attenuation of renal ischemia-reperfusion injury with selectin inhibition in a rabbit model. Am J Surg 1999, 178:573-576.
350. Suri A, Lovitch SB, Unanue ER The wide diversity and complexity of peptides bound to class II MHC molecules. Curr Opin Immunol 2006, 18:70-77.
351. Sutton R, Gray DW, McShane P, et al. The susceptibility of rejection and the absence of susceptibility of pancreatic islet B cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat. J Exp Med 1989, 170:751-762.
352. Swain SL, Weinberg AD, English M, et al. IL-4 directs the development of TH2-like helper effectors. J Immunol 1990, 145:3796-3806.
353. Swain SL, Huston G, Tonkonogy S, et al. Transforming growth factorβ and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 1991, 147:2991-3000.
354. Takeuchi T, Lowry RP, Konieczny B Heart allografts in murine systems. Transplantation 1992, 53:1281-1294.
355. Tesi RJ, Elkhammas EA, Henry ML, et al. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc 1993, 25:901-902. (1 Pt 2).
356. Tewari MK, Sinnathamby G, Rajagopal D, et al. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol 2005, 6:287-294.
357. Tilney NL, Kupiec-Weglinski JW, Heidecke CD, et al. Mechanisms of rejection and prolongation of vascularised organ allografts. Immunol Rev 1984, 77:185-216.
358. Ting A, Morris PJ Renal transplantation and B cell crossmatches with autoantibodies and alloantibodies. Lancet 1977, 2:1095-1097.
359. Tono T, Moden M, Yoshizaki K, et al. Biliary interleukin 6 levels as indicators of hepatic allograft rejection in rats. Transplantation 1992, 53:1195-1201.
360. Toogood GJ, Rankin AM, Tam PKH, et al. The immune response following small bowel transplantation, I: an unusual pattern of cytokine expression. Transplantation 1996, 62:851-855.
361. Toogood GJ, Rankin AM, Tam PKH, et al. The immune response following small bowel transplantation, II: a very early cytokine response in the gut-associated lymphoid tissue. Transplantation 1997, 63:1118-1123.
362. Trowsdale J, Barten R, Haude A, et al. The genomic context of natural killer receptor extended gene families. Immunol Rev 2001, 181:20-38.
363. Tu L, Fang TC, Artis D, et al. Notch signaling is an important regulator of type 2 immunity. J Exp Med 2005, 202:1037-1042.
364. Tullius SG, Heemann UW, Azuma H, et al. Alloantigen-independent factors lead to signs of chronic rejection in long-term kidney isografts. Transpl Int 1994, 7(Suppl 1):S306-S307.
365. Tullius SG, Nieminen M, Bechstein WO, et al. Contribution of early acute rejection episodes to chronic rejection in a rat kidney retransplantation model. Kidney Int 1998, 53:465-472.
366. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992, 89:11102-11105.
367. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 1995, 60:1113-1117.
368. Tybulewicz VL Vav-family proteins in T-cell signalling. Curr Opin Immunol 2005, 17:267-274.
369. Tyler JD, Galli SJ, Snider ME, et al. Cloned LyT-2+ cytolytic T lymphocytes destroy allogeneic tissue in vivo. J Exp Med 1984, 159:234-243.
370. Uehara S, Chase CM, Kitchens WH, et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 2005, 175:3424-3430.
371. van Leeuwen JE, Samelson LE T cell antigen-receptor signal transduction. Curr Opin Immunol 1999, 11:242-248.
372. VanBuskirk AM, Wakely ME, Orosz CG Transfusion of polarized TH2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection. Transplantation 1996, 62:229-238.
373. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
374. Veldhoen M, Hocking RJ, Flavell RA, et al. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006, 7:1151-1156.
375. Verschoor A, Brockman MA, Knipe DM, et al. Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J Immunol 2001, 167:2446-2451.
376. Verschoor A, Brockman MA, Gadjeva M, et al. Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol 2003, 171:5363-5371.
377. Walport MJ Complement: first of two parts. N Engl J Med 2001, 344:1058-1066.
378. Walport MJ Complement: second of two parts. N Engl J Med 2001, 344:1140-1144.
379. Walsh CM, Hayashi F, Saffron DC, et al. Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection. J Immunol 1996, 156:1436-1441.
380. Wang W, Meadows LR, den Haan JMM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995, 269:1588-1590.
381. Watts TH TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
382. Williams GM, Hume DM, Hudson RPJ, et al. "Hyperacute" renal homograft rejection in man. N Engl J Med 1968, 279:611-618.
383. Wolf BA, Hughes JH, Florholmen J, et al. Interleukin-1 inhibits glucose-induced Ca2+ uptake by islets of Langerhans. FEBS Lett 1989, 248:35-38.
384. Wong GHW, Clark-Lewis I, Harris AW, et al. Effect of cloned interferonγ on expression of H-2 and Ia antigens on cell lines of hemopoietic, lymphoid, epithelial, fibroblastic and neuronal origin. Eur J Immunol 1984, 14:52-56.
385. Wong KK, Carpenter MJ, Young LL, et al. Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism. J Clin Invest 2003, 112:1741-1750.
386. Wong WK, Robertson H, Carroll HP, et al. Tubulitis in renal allograft rejection: role of transforming growth factor-beta and interleukin-15 in development and maintenance of CD103+ intraepithelial T cells. Transplantation 2003, 75:505-514.
387. Wood KJ, Sawitzki B Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol 2006, 27:183-187.
388. Yamada A, Laufer TM, Gerth AJ, et al. Further analysis of the T-cell subsets and pathways of murine cardiac allograft rejection. Am J Transplant 2003, 3:23-27.
389. Yang HC, McElroy RJ, Kreider JW, et al. In situ expression of platelet-derived growth factor (PDGF-beta) during chronic rejection is abolished by retransplantation. J Surg Res 1995, 59:205-210.
390. Yopp AC, Krieger NR, Ochando JC, et al. Therapeutic manipulation of T cell chemotaxis in transplantation. Curr Opin Immunol 2004, 16:571-577.
391. Zelenika D, Adams E, Mellor A, et al. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol 1998, 161:1868-1874.
392. Zhou W, Patel H, Li K, et al. Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 2006, 107:2461-2469.
393. Zhou W, Peng Q, Li K, et al. Role of dendritic cell synthesis of complement in the allospecific T cell response. Mol Immunol 2007, 44(1-3):57-63.
394. Zimmerman C, Seiler P, Lane P, et al. Antiviral immune responses in CTLA4 transgenic mice. J Virol 1997, 71:1802-1807.